Cephalon touts new pain study data

Cephalon announced that a Phase III trial of Fentora demonstrated a statistically significant response for lower back pain. Fentora is approved as a therapy for cancer pain. In the trial, Fentora provided significant relief within 10 minutes compared to a placebo. Fentora is an oral therapy absorbed through the lining of the cheek. Cephalon shares were buoyed by the announcement.

- Here's the AP report on Fentora

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.